

Applicants: Ellen W. Collisson, et al.

U.S. Serial No.: 08/303,510

Filed: April 30, 1999

Page 8

In reply, applicants submit herewith a revised Sequence Listing attached hereto as **Exhibit B** in compliance with the requirements of 37 C.F.R. §1.824. In addition, applicants submit herewith a computer readable copy of the Sequence Listing on the enclosed computer diskette, which has the same content as the paper copy attached as **Exhibit B**. Applicants submit as **Exhibit C**, a Statement in accordance with 37 C.F.R. §1.821(f) certifying that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information which is submitted herewith as **Exhibit B** entitled "Sequence Listing".

Thus, applicants maintain that the application now complies with the requirements of 37 C.F.R. §1.824 and request that the Examiner withdraw this objection.

Restriction

The examiner requires restriction to the invention of Group I (nucleic acid), the invention of Group II (plasmid vectors and host cells), the invention of Group III (polypeptides and method for increasing an immune response), or the invention of Group IV (polypeptides and method for suppressing an immune response).

The examiner further requires restriction of a single species selected from CD80, CD86, CD28 and CTLA-4. Applicants hereby elect for prosecution on the merits nucleic acids (Group I) encoding feline CD86. Applicants respectfully traverse the examiner's restriction requirement as it relates to Groups I and II. All vector claims comprise nucleic acid encoding CD86. It is respectfully requested that claims 55, 56, 61-64 and 84-88 (vectors

Applicants: Ellen W. Collisson, et al.
U.S. Serial No.: 08/303,510
Filed: April 30, 1999
Page 9

and host cells comprising such vectors) be examined with the invention of Group I.


Claims 1, 3-5, 7, 8, 53, 54, 57-60 and 65-82 have been canceled without prejudice to applicants' right to pursue the subject matter of these claims in a future application. New claims 83-88 have been added. Claims 2, 6, 46-52, 55, 56, 61-64 and 83-88 are presented for examination on the merits. All pending claims are readable upon the elected invention. Early and favorable action is solicited.

If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.


Applicants: Ellen W. Collisson, et al.
U.S. Serial No.: 08/303,510
Filed: April 30, 1999
Page 10

No fee other than the enclosed fee of \$110.00 for a one-month extension of time is believed to be necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
	11/18/00
John P. White Reg. No. 28,678	Date